Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer

被引:11
|
作者
Liu, Zhi Bing [1 ]
Zhang, Luyan [2 ]
Bian, Jia [3 ]
Jian, Jinbo [1 ]
机构
[1] Binzhou Med Univ Hosp, Dept Oncol, Binzhou 256600, Shandong, Peoples R China
[2] Binzhou Peoples Hosp, Dept Oncol, Binzhou 256600, Shandong, Peoples R China
[3] Binzhou Med Univ Hosp, Dept Radiol, Binzhou 256600, Shandong, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2020年 / 13卷
关键词
immunotherapy; breast; cancer; combination; PD-L1; EXPRESSION; IPILIMUMAB; ANTIBODY; CTLA-4; IDENTIFICATION; PEMBROLIZUMAB; TREMELIMUMAB; ABEMACICLIB; NIVOLUMAB; RADIATION;
D O I
10.2147/OTT.S240655
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Checkpoint immunotherapy is emerging as a newtherapeutic approach for metastatic breast cancer. Monotherapy of immunoagents against PD1/PD-L1 or CTLA-4 has shown little efficacy in these patients. Recently, to determine the optimal use of immunotherapy, there has been a rapid expansion in the number of clinical trials developing immunotherapy combinations. These combination therapeutic approaches can enhance various aspects of cancer immunity, such as tumor antigenicity or intratumor T cell infiltration, which provides a theoretical basis for combining them with checkpoint immunotherapy to achieve synergistic effects. Here, we review the available data and ongoing efforts to establish the safety and efficacy of immunoagents in combination with chemotherapy, radiotherapy, HER2-targeted therapy, CDK4/6 inhibitors, PARP inhibitors, and another checkpoint immunoagents.
引用
收藏
页码:2657 / 2666
页数:10
相关论文
共 50 条
  • [1] Combination Immunotherapy Strategies in Breast Cancer
    Chun, Brie M.
    Page, David B.
    McArthur, Heather L.
    CURRENT BREAST CANCER REPORTS, 2019, 11 (04) : 228 - 240
  • [2] Combination Immunotherapy Strategies in Breast Cancer
    Brie M. Chun
    David B. Page
    Heather L. McArthur
    Current Breast Cancer Reports, 2019, 11 : 228 - 240
  • [3] Emerging strategies for combination checkpoint modulators in cancer immunotherapy
    Popovic, Aleksandra
    Jaffee, Elizabeth M.
    Zaidi, Neeha
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (08): : 3209 - 3218
  • [4] Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
    Marquez-Garban, Diana C.
    Deng, Gang
    Comin-Anduix, Begonya
    Garcia, Alejandro J.
    Xing, Yanpeng
    Chen, Hsiao-Wang
    Cheung-Lau, Gardenia
    Hamilton, Nalo
    Jung, Michael E.
    Pietras, Richard J.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2019, 193
  • [5] Immunotherapy for the Treatment of Breast Cancer: Checkpoint Blockade, Cancer Vaccines, and Future Directions in Combination Immunotherapy
    McArthur, Heather L.
    Page, David B.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 922 - 933
  • [6] Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines
    Sanchez, Katherine
    Page, David
    McArthur, Heather L.
    CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 151 - 162
  • [7] Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies
    Evanthia T. Roussos Torres
    Leisha A. Emens
    Breast Cancer Research and Treatment, 2022, 191 : 291 - 302
  • [8] Immunotherapy of metastatic breast cancer
    Hartkopf, Andreas Daniel
    ONKOLOGIE, 2024, 30 (06): : 485 - 489
  • [9] Immunotherapy for metastatic breast cancer
    Sugie, Tomoharu
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [10] The combination of checkpoint immunotherapy and targeted therapy in cancer
    Karachaliou, Niki
    Gonzalez-Cao, Maria
    Sosa, Aaron
    Berenguer, Jordi
    Paulina Bracht, Jillian Wilhelmina
    Ito, Masaoki
    Rosell, Rafael
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (19) : 1 - 10